Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

ANL vs SANA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

SANA Captures Overall Composite Edge (44.3 HOLD vs 48.3 HOLD), While ANL Leads 3–2 on Growth & Valuation Pillars

SANA Overall Winner 6-Pillar Tally: ANL 3 – 2 SANA (1 Tie) Matrix Metrics: ANL 5 – 3 SANA

As of Nov 16, 2026, Sana Biotechnology, Inc. (SANA) captures the overall head-to-head institutional edge over ANL (ANL) on higher Unified Composite conviction (44.3/100 HOLD vs. 48.3/100 HOLD) after splitting the core matrix 3–5 (led by Profitability & Quality, Options & Positioning), while ANL wins 3–2 across the 6-pillar growth and valuation breakdown. ANL trades at $10.03 (N/M Forward P/E, -123.5% operating margin) versus SANA at $1.88 (N/M Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While ANL currently prints a higher short-term Unified Composite Score (48.3/100 HOLD vs. SANA 44.3/100 HOLD), SANA captures the overall institutional head-to-head verdict (3–5 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -123.5% operating margin) and revenue trajectory (+0.0% vs. +178.1% YoY).
  • Technical & Structure Timing Caution: ANL is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 41.7); meanwhile SANA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 30.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ANL vs SANA
ANL US Equity
ANL
Institutional Equity
$10.03
-5.47% 1D
Market Cap $683.3M
TTM Revenue $18M
Forward P/E N/M
Beta / 30D Vol 2.64β · 81% Vol
Unified Composite Score
48.3 / 100 HOLD
Tech 48.0 Fund 52.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -9.9%), weak momentum, RSI 42
RSI-14: 41.7 · SMA20: $10.30 · SMA50: $12.92
SANA NASDAQ Head-to-Head Winner
Sana Biotechnology, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$1.88
-6.93% 1D
Market Cap $605.3M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.82β · 78% Vol
Unified Composite Score
44.3 / 100 HOLD
Tech 33.0 Fund 51.0 Flow 66.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -18.0%), weak momentum, RSI 31
RSI-14: 30.6 · SMA20: $2.37 · SMA50: $2.68

6-Pillar Scorecard Institutional Category Breakdown (ANL 3 – 2 SANA)

Columns: Metric · ANL · SANA
1. Valuation Multiples ANL
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 37.8x N/M
2. Growth & Scale ANL
Revenue Growth (YoY) +178.1% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $18M N/A
Market Cap $683.3M $605.3M
3. Profitability & Quality SANA
Gross Margin 100.0% N/A
Operating Margin -123.5% 0.0%
Net Profit Margin -124.8% 0.0%
Return on Equity (ROE) -20.2% -79.5%
4. Balance Sheet & Cash Flow ANL
Cash Generation (TTM) -$22M EBITDA -$145M
Cash Flow Margin -119.9% EBITDA Mgn N/A
Net Cash / Leverage $3.34 Book/Sh · -20.2% ROE $13M Net Debt (0.30x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning SANA
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile N/A (N/A) 105.5% (4th %ile)
Put/Call OI Skew N/A 0.61x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ANL (5) vs SANA (3)
Institutional Metric ANL SANA Criterion Row Edge
Market Capitalization
Scale
$683.3M $605.3M Larger Scale ANL
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+178.1% +0.0% Higher Growth ANL
Operating Margin (TTM)
Profitability
-123.5% 0.0% Higher Margin SANA
Net Profit Margin
Profitability
-124.8% 0.0% Higher Margin SANA
Return on Equity (ROE)
Capital Efficiency
-20.2% -79.5% Higher ROE ANL
52-Week Range Position
Momentum
56% ($1–$17) 1% ($2–$5) Stronger Trend ANL
Beta / 30D Volatility
Risk Regime
2.64β · 81% Vol 1.82β · 78% Vol Lower Realized Risk SANA
Unified Institutional Score
Composite Signal
48.3 / 100 (HOLD) 44.3 / 100 (HOLD) Higher Composite ANL
Trailing 12M Revenue (USD)
Operating Scale
$18M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
100.0% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 37.8x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$22M EBITDA ($3.34 Book/Sh · -20.2% ROE) -$145M ($13M Net Debt (0.30x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ANL +8.11 pp
ANL: -9.07% · SANA: -17.18%
3M Horizon ANL +19.04 pp
ANL: -29.17% · SANA: -48.21%
6M Horizon ANL +24.55 pp
ANL: -13.61% · SANA: -38.16%
1Y Horizon ANL +612.87 pp
ANL: +564.24% · SANA: -48.63%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ANL vs SANA. Trailing 12-month operating profitability (ANL -123.5% vs SANA 0.0%) and valuation multiples (ANL N/M vs SANA N/M Forward P/E) are benchmarked directly in Pillar 4 below.

ANL ADR TTM Benchmark FX-Normalized USD
TTM Revenue$18M
Gross Margin100.0%
Op. Margin-123.5%
ROE / Fwd P/E-20.2% · N/M
SANA ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-79.5% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ANL UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ANL Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
SANA BREAKDOWN
57d in phase · OBV NEUTRAL
Current IV 105.5%
IV Percentile 4th %ile
Put/Call OI Skew 0.61x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact SANA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ANL Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $683.3M market capitalization and -123.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
SANA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $605.3M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ANL vs SANA Key Questions & Quantitative Answers

As of Nov 16, 2026, Sana Biotechnology, Inc. (SANA) captures the overall head-to-head institutional edge over ANL (ANL) on higher Unified Composite conviction (44.3/100 HOLD vs. 48.3/100 HOLD) after splitting the core matrix 3–5 (led by Profitability & Quality, Options & Positioning), while ANL wins 3–2 across the 6-pillar growth and valuation breakdown. ANL trades at $10.03 (N/M Forward P/E, -123.5% operating margin) versus SANA at $1.88 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While ANL currently prints a higher short-term Unified Composite Score (48.3/100 HOLD vs. SANA 44.3/100 HOLD), SANA captures the overall institutional head-to-head verdict (3–5 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -123.5% operating margin) and revenue trajectory (+0.0% vs. +178.1% YoY). Technical & Structure Timing Caution: ANL is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 41.7); meanwhile SANA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 30.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ANL leads the Growth & Scale pillar: ANL posts +178.1% YoY revenue growth and +0.0% YoY earnings growth on $18M TTM revenue (100.0% gross margin, -123.5% operating margin), compared with SANA at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, ANL generates $18M in USD-normalized revenue versus N/A for SANA. In operating R&D and SG&A reinvestment, ANL deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for SANA.

ANL screens cheaper on headline valuation multiples. ANL trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 37.8x EV/Revenue (-119.9% EBITDA margin), whereas SANA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ANL (-20.2% ROE) versus SANA (-79.5% ROE) capital efficiency.

In options market volatility and institutional positioning, ANL carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (2.64β · 81% Vol realized risk). By comparison, SANA carries 105.5% implied volatility (4th %ile, Compressed (<25th %ile)), a 0.61x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.82β · 78% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.